Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein‑47 and collagen type I in rat hepatic stellate cells in vitro
Molecular medicine reports, Jan 3, 2015
Pirfenidone (esbiret) is an established anti‑fibrotic and anti‑inflammatory drug used to treat id... more Pirfenidone (esbiret) is an established anti‑fibrotic and anti‑inflammatory drug used to treat idiopathic pulmonary fibrosis. In the present study, the dose‑dependent effects of pirfenidone on the cell cycle, proliferation and expression of heat shock protein (HSP)‑47 and collagen type I in a cultured rat hepatic stellate cell line (HSC‑T6) were investigated. Following pirfenidone treatment, cell proliferation was determined using the cell counting kit‑8 assay and the cell cycle was measured using flow cytometry. HSP‑47 expression was estimated using western blot analysis and collagen type I mRNA was assessed using reverse transcription quantitative polymerase chain reaction. Pirfenidone induced significant dose‑dependent inhibition of proliferation in HSC‑T6 cells. Cell viability was unaffected by treatment with pirfenidone (0, 10 or 100 µM) for 24 and 72 h. However, after 24 h, HSC‑T6 cells exhibited dose‑dependent decreases in HSP‑47 protein and collagen I mRNA levels. In conclusion, pirfenidone inhibited HSC‑T6 cell proliferation, arrested the cell cycle and reduced the expression of HSP‑47 and collagen type I, indicating that pirfenidone may be a promising drug in the treatment of liver fibrosis.
Uploads
Papers by Xing Li